Markets

Celgene Presents Positive SPRINT Study Data on Revlimid - Analyst Blog

Celgene CorporationCELG presented two analyses of the MCL-002 (SPRINT) study on Revlimid in patients with relapsed/refractory mantle cell lymphoma (MCL) at the European Hematology Association annual congress.

In the randomized, multi-center, open-label, phase II SPRINT study, Revlimid was compared to an investigators' choice/IC (single agent cytarabine, rituximab, gemcitabine, fludarabine or chlorambucil) in patients with relapsed/refractory MCL.

The study met the primary endpoint with median progression-free survival being 8.7 months for patients in the Revlimid arm compared with 5.2 months in the IC arm. In a pre-specified exploratory analysis, it was found that Revlimid provided a reduction in the risk of progression or death as compared to each IC treatment - cytarabine, rituximab, gemcitabine, fludarabine or chlorambucil. Meanwhile, patients treated with Revlimid reported a similar quality of life (measured by using the EORTC QLQ-C30) as IC single agents across all domain/scale scores and at each follow-up visit during the study.

Revlimid is approved in many countries across the globe in combination with dexamethasone for treating multiple myeloma (MM) patients, who have received at least one prior therapy. Revlimid is also approved in the U.S. in the relapsed refractory MCL indication.

Revlimid is also available in many countries for treating transfusion-dependent anemia due to low or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality (with or without additional cytogenetic irregularities). Celgene is looking to expand the drug's label. In 2014, Revlimid generated revenues of approximately $5 billion, accounting for almost 65% of Celgene's revenues.

Celgene carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Actelion Ltd. ALIOF , Valeant Pharmaceuticals International, Inc. VRX and Gilead Sciences Inc. GILD . All three sport a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

CELGENE CORP (CELG): Free Stock Analysis Report

ACTELION LTD (ALIOF): Free Stock Analysis Report

VALEANT PHARMA (VRX): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GILD CELG

Other Topics

Stocks